GlassScriptPhysician profile
Michael A Schindel
NPI 1881778256
$16,186.04
in general payments reported to CMS, 2019-2025
71 companies · $1,616 in 2025
The $1,616 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,417 · 2020: $1,871 · 2021: $2,949 · 2022: $2,305 · 2023: $2,415 · 2024: $2,612 · 2025: $1,616.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,644.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,644.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,392.99 | 2019-2025 | Vraylar, Ubrelvy, Linzess |
| Astrazeneca Pharmaceuticals LP | $1,234.15 | 2019-2025 | Airsupra, Nexium, Breztri |
| Janssen Pharmaceuticals, INC | $1,010.35 | 2019-2025 | Xarelto, Spravato |
| Amgen INC. | $984.13 | 2019-2025 | Repatha, Otezla, Evenity |
| Novo Nordisk INC | $778.51 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $758.47 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $703.26 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $676.75 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $656.01 | 2019-2025 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $614.07 | 2019-2025 | Rexulti |
| Supernus Pharmaceuticals, INC. | $524.93 | 2023-2024 | Qelbree, Qelbree |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $372.23 | 2019-2025 | Xifaxan, Trulance |
| Merck Sharp & Dohme LLC | $350.04 | 2019-2025 | Gardasil 9, Vaxneuvance, Capvaxive |
| Esperion Therapeutics, INC. | $336.21 | 2020-2025 | Nexletol |
| Gilead Sciences, INC. | $286.35 | 2019-2025 |
Show all 71 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Schindel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.